Holen Sie sich die Stockscreener-App
17.57
25.48%
-5.445
Schlusskurs vom Vortag:
$23.02
Offen:
$17.83
24-Stunden-Volumen:
63.83M
Relative Volume:
3.23
Marktkapitalisierung:
$3.93B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
25.47
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-35.12%
1M Leistung:
-45.87%
6M Leistung:
-66.97%
1J Leistung:
-59.68%
1-Tages-Spanne:
$16.35
$17.90
1-Wochen-Bereich:
$16.35
$27.77
52-Wochen-Spanne:
$16.35
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs ZTS, TAK, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
17.26 | 5.24B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
126.97 | 56.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.61 | 56.52B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
HLN
Haleon Plc Adr
|
10.85 | 48.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.47 | 39.90B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.11 | 20.90B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Stock Movers: Alphabet, Hims & Hers Health, Tegna - Bloomberg.com
Kyndryl, Hims & Hers, Novo Nordisk, Valaris, Monday.com, Cleveland-Cliffs, and More Movers - Barron's
Gottlieb says Hims & Hers risks DOJ action over unapproved GLP-1 rival to Novo Nordisk- CNBC interview - Seeking Alpha
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs - Benzinga
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs - Benzinga
Novo-Nordisk A/S rose more than 5% at the market opening as its competitor HIMS withdrew plans for a low-cost generic weight-loss drug. - 富途牛牛
Eli Lilly buys Orna, Novo Nordisk sues Hims & Hers, Kyndryl plunges - Yahoo Finance
Novo says it’s suing Hims to halt obesity drug copycats - The Detroit News
Novo files patent suit against Hims (update) (HIMS:NYSE) - Seeking Alpha
Shake-up in HIMS and Novo Nordisk shares⚡A lawsuit in the background... 🏛️ - XTB.com
Stock Movers: Hims & Hers, Eli Lilly, Alphabet - Bloomberg.com
Hims & Hers scraps low-cost weight-loss pill following backlash - Proactive financial news
'Health Risk': Novo Nordisk Sues Hims & Hers Over Cheaper Version Of Ozempic, Wegovy Fat Loss Pills - NDTV Profit
Novo Says It’s Suing Hims to Halt Obesity Drug Copycats - Bloomberg.com
AI for investors - MLQ.ai
Morning Market Movers: UOKA, KD, HIMS, PGY See Big Swings - RTTNews
Novo Nordisk sues Hims & Hers over patent infringement - WKZO
Needham maintains Hold on Hims and Hers stock amid FDA scrutiny - Investing.com
Stocks to Watch Monday: Novo Nordisk, Hims & Hers, Apollo - The Wall Street Journal
These Stocks Are Today’s Movers: Kyndryl, Hims & Hers, Novo Nordisk, Kroger, Nvidia, Monday.com, and More - Barron's
Assessing Hims & Hers Health (HIMS) Valuation After Compounded GLP-1 Launch And Rapid Regulatory Retreat - Yahoo Finance
Hims & Hers Stock Plunges. Its Weight Loss Drug Strategy Backfired. - Barron's
Novo Nordisk Sues Hims & Hers, Seeking Ban on Copycat Drugs and Damages - Yahoo Finance
Novo Nordisk Surges as Hims & Hers Withdraws Weight-Loss Pill - GuruFocus
Hims and Hers stock maintains Buy rating at BTIG despite GLP-1 pill withdrawal - Investing.com
Hims & Hers Pulls Compounded Weight-Loss Pill After FDA Warning - GuruFocus
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks - Stocktwits
S&P 500 Futures Decline in Premarket Trading; Kyndryl Holdings, Hims & Hers Health Lag - Barron's
Novo sues Hims, alleging patent infringement - Sherwood News
Novo Says It’s Suing Hims to Halt Obesity Drug Copycats (1) - Bloomberg Law News
Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill - The Wall Street Journal
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (4 Ratings) - Benzinga
Hims & Hers (HIMS) Retreats from Wegovy Knockoff Plan - GuruFocus
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs - Financial Times
Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic® - Yahoo Finance
Novo Nordisk Shares Jump After Hims & Hers Scraps Plan for Copycat Weight-Loss Pill - The Wall Street Journal
Hims and Hers stock price target lowered by BofA amid FDA restrictions - Investing.com
Hims & Hers, Novo Nordisk, Micron, Kroger, STMicroelectronics, Dynatrace, and More Movers - Barron's
Hims & Hers retreats from compounded GLP-1 pill - Axios
Novo soars, Hims & Hers sinks, following compounded drug drama (NVO:NYSE) - Seeking Alpha
These Stocks Are Today’s Movers: Hims & Hers, Micron, Kroger, STMicroelectronics, Nvidia, Amazon, and More - Barron's
Crypto-linked stocks slide as bitcoin tumbles back below $70,000 - Sherwood News
Novo Nordisk shares rise as Hims abandons $49 weight-loss pill - Yahoo Finance
Tensions are compounding in the weight loss drug market - Morning Brew
Novo Nordisk jumps, Hims shares nosedive after pulling $49 weight-loss pill - Investing.com
Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow. - Barron's
Biggest stock movers Monday: SOFI, HIMS, and more (NASDAQ:SOFI) - Seeking Alpha
Novo Nordisk Shares Jump After Hims & Hers Scraps Plan For Copycat Weight-Loss Pill - The Wall Street Journal
FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin - Chartmill
Hims & Hers: Decelerating Growth And Cowboy Management, Material Downside Risk (NYSE:HIMS) - Seeking Alpha
Hims & Hers reverses plan for oral Wegovy, and its stock tumbled 20% - MarketWatch
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):